Revisional endoscopic sleeve gastroplasty versus semaglutide and tirzepatide for weight recidivism after sleeve gastrectomy
In a single-centre real-world experience study, R-ESG and tirzepatide appear to offer more weight loss than semaglutide in SG patients with weight recidivism although GLP1/GIP-RA were underdosed. GLP1/GIP-RA achieved higher weight loss in patients with intact stomach than those with prior SG.
Authors
- Erik Dutson (ORCID: https://orcid.org/0000-0001-7126-1468)
- Na Shen (ORCID: https://orcid.org/0000-0003-2473-559X)
- V. Raman Muthusamy (ORCID: https://orcid.org/0000-0003-1602-1335)
- Alireza Sedarat
- Firas Bahdi (ORCID: https://orcid.org/0000-0002-3754-324X)
- Fadi Dahoud
- Maryam Farooq
- Jennifer M. Kolb (ORCID: https://orcid.org/0000-0002-6352-0797)
- Philip Kozan
- Adarsh M. Thaker (ORCID: https://orcid.org/0000-0002-8549-7778)
- Sagar Shah (ORCID: https://orcid.org/0000-0002-3592-2270)
- Danny Issa (ORCID: https://orcid.org/0000-0002-0343-1397)
- Stephen Kim (ORCID: https://orcid.org/0009-0008-4986-3233)
Institutions
- University of California, Los Angeles (US)
Publication Details
- Journal
- Clinical Obesity
- Published
- 2025-02-05
- DOI
- https://doi.org/10.1111/cob.70001
- Citations
- 6
- Primary Topic
- Bariatric Surgery and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 12.04